文献速递肿瘤 PET/CT

99mTc-马拉克拉肽与99mTc-甲氧基异丁基异腈分子乳腺成像在疑似乳腺癌患者中的比较

Comparison of Tc-99m maraciclatide and Tc-99m sestamibi molecular breast imaging in patients with suspected breast cancer.
PubMed 文献 · EJNMMI Res · 2017-01-14

本研究纳入疑似乳腺癌女性,分别行99mTc-甲氧基异丁基异腈(sestamibi)与99mTc-马拉克拉肽(maraciclatide)分子乳腺成像(MBI)。39例可分析患者中21例确诊恶性肿瘤,两种显像剂对恶性病灶检出率、病灶范围与病理大小相关性、病灶/本底比值及整体诊断效能均相似,马拉克拉肽灵敏度呈边缘性(但无统计学意义)提高。

要点

  • 99mTc-马拉克拉肽与99mTc-sestamibi对恶性病灶检出率相似(90% vs 86%,p=1)。
  • 两种显像剂病灶范围与病理大小均强相关(r=0.84与r=0.81)。
  • 两药病灶/本底比值及ROC曲线下面积均无显著差异,分子亚型与摄取无相关性。

核心结论

  • 99mTc-马拉克拉肽在恶性与良性病灶中的摄取与99mTc-sestamibi相当。
  • 两种显像剂测量的病灶范围与摄取均呈良好相关性。
  • 99mTc-马拉克拉肽较99mTc-sestamibi灵敏度呈边缘性(但无统计学意义)提高。
  • 研究结果不支持任一显像剂摄取与肿瘤分子亚型存在关联。

研究设计与样本

  • 疑似乳腺癌女性被招募接受两次MBI检查,一次使用99mTc-sestamibi,一次使用99mTc-maraciclatide,采用高分辨率专用伽马相机。
  • 放射科医师以随机、盲法方式判读MBI,赋予评估评分(1-5分)并测量病灶大小。
  • 通过感兴趣区分析测量病灶/本底(L/B)比值。
  • 39例可分析患者中,21例患者共检出21个恶性肿瘤。

主要发现

  • 21个恶性肿瘤中,99mTc-sestamibi MBI检出18个(86%),99mTc-maraciclatide MBI检出19个(90%),p=1。
  • 肿瘤范围与病理大小强相关:99mTc-sestamibi r=0.84,99mTc-maraciclatide r=0.81。
  • 检出乳腺癌的L/B比值:99mTc-sestamibi 1.55±0.36,99mTc-maraciclatide 1.62±0.37,p=0.53。
  • 20个良性病灶中,99mTc-sestamibi检出10个(50%),99mTc-maraciclatide检出9个(45%),p=0.1;良性病灶平均L/B比值分别为1.34±0.40与1.41±0.52,p=0.75。
  • ROC分析AUC:99mTc-sestamibi 0.83,99mTc-maraciclatide 0.87,p=0.64。

关键数值与推荐

  • 恶性病灶检出率:99mTc-sestamibi 86%(18/21)vs 99mTc-maraciclatide 90%(19/21),p=1。
  • 肿瘤范围与病理大小相关系数:99mTc-sestamibi r=0.84,99mTc-maraciclatide r=0.81。
  • 恶性病灶L/B比值:99mTc-sestamibi 1.55±0.36 vs 99mTc-maraciclatide 1.62±0.37,p=0.53。
  • 良性病灶L/B比值:99mTc-sestamibi 1.34±0.40 vs 99mTc-maraciclatide 1.41±0.52,p=0.75。
  • ROC AUC:99mTc-sestamibi 0.83 vs 99mTc-maraciclatide 0.87,p=0.64。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Molecular breast imaging (MBI) performed with 99mTc sestamibi has been shown to be a valuable technique for the detection of breast cancer. Alternative radiotracers such as 99mTc maraciclatide may offer improved uptake in breast lesions. The purpose of this study was to compare relative performance of 99mTc sestamibi and 99mTc maraciclatide in patients with suspected breast cancer, using a high-resolution dedicated gamma camera for MBI. Women with breast lesions suspicious for malignancy were recruited to undergo two MBI examinations-one with 99mTc sestamibi and one with 99mTc maraciclatide. A radiologist interpreted MBI studies in a randomized, blinded fashion to assign an assessment score (1-5) and measured lesion size. Lesion-to-background (L/B) ratio was measured with region-of-interest analysis. RESULTS: Among 39 analyzable patients, 21 malignant tumors were identified in 21 patients. Eighteen of 21 tumors (86%) were seen on 99mTc sestamibi MBI and 19 of 21 (90%) were seen on 99mTc maraciclatide MBI (p = 1). Tumor extent measured with both radiopharmaceuticals correlated strongly with pathologic size (99mTc sestamibi, r = 0.84; 99mTc maraciclatide, r = 0.81). The L/B ratio in detected breast cancers was similar for the two radiopharmaceuticals: 1.55 ± 0.36 (mean ± S.D.) for 99mTc sestamibi and 1.62 ± 0.37 (mean ± S.D.) for 99mTc maraciclatide (p = 0.53). No correlation was found between the L/B ratio and molecular subtype for 99mTc sestamibi (r s = 0.12, p = 0.63) or 99mTc maraciclatide (r s = -0.12, p = 0.64). Of 20 benign lesions, 10 (50%) were seen on 99mTc sestamibi and 9 of 20 (45%) were seen on 99mTc maraciclatide images (p = 0.1). The average L/B ratio for benign lesions was 1.34 ±0.40 (mean ±S.D.) for 99mTc sestamibi and 1.41 ±0.52 (mean ±S.D.) for 99mTc maraciclatide (p = 0.75). Overall diagnostic performance was similar for both radiopharmaceuticals. AUC from ROC analysis was 0.83 for 99mTc sestamibi and 0.87 for 99mTc maraciclatide (p = 0.64). CONCLUSIONS: 99mTc maraciclatide offered comparable lesion uptake to 99mTc sestamibi, in both malignant and benign lesions. There was good correlation between lesion extent and uptake measured from both radiopharmaceuticals. 99mTc maraciclatide offered a marginal (but not significant) improvement in sensitivity over 99mTc sestamibi. Our findings did not support an association between the uptake of either radiopharmaceutical and tumor molecular subtype. TRIAL REGISTRATION: ClinicalTrials.gov, NCT00888589.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. O'Connor MK, Morrow MMB, Hunt KN, et al. Comparison of Tc-99m maraciclatide and Tc-99m sestamibi molecular breast imaging in patients with suspected breast cancer. EJNMMI Res. 2017. PMID: 28091980. doi:10.1186/s13550-017-0255-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。